AU2016257911B2 - Compositions and methods for delivering therapeutic agents into the colon - Google Patents

Compositions and methods for delivering therapeutic agents into the colon Download PDF

Info

Publication number
AU2016257911B2
AU2016257911B2 AU2016257911A AU2016257911A AU2016257911B2 AU 2016257911 B2 AU2016257911 B2 AU 2016257911B2 AU 2016257911 A AU2016257911 A AU 2016257911A AU 2016257911 A AU2016257911 A AU 2016257911A AU 2016257911 B2 AU2016257911 B2 AU 2016257911B2
Authority
AU
Australia
Prior art keywords
composition according
mixture
enema composition
enema
block copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016257911A
Other languages
English (en)
Other versions
AU2016257911A1 (en
Inventor
Aida Habtezion
Ravinder D. Pamnani
Jayakumar Rajadas
Sidhartha Ranjit SINHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2016257911A1 publication Critical patent/AU2016257911A1/en
Application granted granted Critical
Publication of AU2016257911B2 publication Critical patent/AU2016257911B2/en
Priority to AU2021203094A priority Critical patent/AU2021203094A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016257911A 2015-05-04 2016-05-04 Compositions and methods for delivering therapeutic agents into the colon Active AU2016257911B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021203094A AU2021203094A1 (en) 2015-05-04 2021-05-14 Compositions and methods for delivering therapeutic agents into the colon

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562156682P 2015-05-04 2015-05-04
US62/156,682 2015-05-04
PCT/US2016/030682 WO2016179227A1 (en) 2015-05-04 2016-05-04 Compositions and methods for delivering therapeutic agents into the colon

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021203094A Division AU2021203094A1 (en) 2015-05-04 2021-05-14 Compositions and methods for delivering therapeutic agents into the colon

Publications (2)

Publication Number Publication Date
AU2016257911A1 AU2016257911A1 (en) 2017-11-09
AU2016257911B2 true AU2016257911B2 (en) 2021-02-18

Family

ID=57218315

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016257911A Active AU2016257911B2 (en) 2015-05-04 2016-05-04 Compositions and methods for delivering therapeutic agents into the colon
AU2021203094A Abandoned AU2021203094A1 (en) 2015-05-04 2021-05-14 Compositions and methods for delivering therapeutic agents into the colon

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021203094A Abandoned AU2021203094A1 (en) 2015-05-04 2021-05-14 Compositions and methods for delivering therapeutic agents into the colon

Country Status (9)

Country Link
US (3) US20180140619A1 (enExample)
EP (2) EP3291818B1 (enExample)
JP (1) JP6814162B2 (enExample)
KR (1) KR20170142181A (enExample)
AU (2) AU2016257911B2 (enExample)
CA (1) CA2984111A1 (enExample)
DK (1) DK3291818T3 (enExample)
ES (1) ES2761636T3 (enExample)
WO (1) WO2016179227A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191547A1 (en) * 2014-06-09 2015-12-17 Cornell University Implantable therapeutic delivery system and methods thereof
CA2984111A1 (en) * 2015-05-04 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivering therapeutic agents into the colon
PL3870226T3 (pl) * 2018-10-24 2023-12-27 Ferring B.V. Mukoadhezyjne kompozycje farmaceutyczne kortykosteroidów
US20210361602A1 (en) * 2020-05-22 2021-11-25 Intact Therapeutics, Inc. Dosing methods for treating inflammatory bowel conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350690A (en) * 1980-10-27 1982-09-21 Cressington Investments Ltd. Steroid composition
US4765987A (en) * 1985-08-30 1988-08-23 Adir & Cie Artificial surfactants, pharmaceutical compositions containing them and use thereof
US20080020056A1 (en) * 2006-07-19 2008-01-24 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
US20120111756A1 (en) * 2008-12-17 2012-05-10 Altheus Therapeutics, Inc. Enema formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
CA2984111A1 (en) * 2015-05-04 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivering therapeutic agents into the colon

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350690A (en) * 1980-10-27 1982-09-21 Cressington Investments Ltd. Steroid composition
US4765987A (en) * 1985-08-30 1988-08-23 Adir & Cie Artificial surfactants, pharmaceutical compositions containing them and use thereof
US20080020056A1 (en) * 2006-07-19 2008-01-24 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
US20120111756A1 (en) * 2008-12-17 2012-05-10 Altheus Therapeutics, Inc. Enema formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV, Clinical Trials, (2012-11), pages 1 - 6, URL: https://clinicaltrials.gov/ct2/show/NCT01008410?term=NCT01008410&rank=1, (2016-06-28) *
KIM, DW et al., "The Influence of Bile Salt on the Chemotherapeutic Response of Docetaxel-Loaded Thermosensitive Nanomicelles.", International Journal of Nanomedicine., (2014-08-08), vol. 9, no. 1, pages 3816 - 3824 *
MOLOUGHNEY, JG et al., "Poloxamer 188 (P188) as a Membrane Resealing Reagent in Biomedical Applications.", Recent Patents on Biotechnology., (2012-12), vol. 6, no. 3, pages 1 - 21 *

Also Published As

Publication number Publication date
DK3291818T3 (da) 2019-12-09
EP3291818A1 (en) 2018-03-14
JP6814162B2 (ja) 2021-01-13
EP3659607A1 (en) 2020-06-03
US20180140619A1 (en) 2018-05-24
KR20170142181A (ko) 2017-12-27
ES2761636T3 (es) 2020-05-20
CA2984111A1 (en) 2016-11-10
JP2018515511A (ja) 2018-06-14
US20210283148A1 (en) 2021-09-16
EP3291818B1 (en) 2019-10-30
AU2016257911A1 (en) 2017-11-09
US20210330682A1 (en) 2021-10-28
EP3291818A4 (en) 2018-12-12
AU2021203094A1 (en) 2021-06-10
WO2016179227A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
AU2021203094A1 (en) Compositions and methods for delivering therapeutic agents into the colon
JP2000505430A (ja) ニコチンの結腸送達による炎症性腸疾患の治療
AU2017205337B2 (en) Formulations for treating bladder cancer
US12171747B2 (en) Material and method for treating cancer
ES2260321T3 (es) Composicion para el tratamiento de transtornos inflamatorios.
TW202426000A (zh) 包含５－膽甾烯－３，２５－二醇３－硫酸酯（２５ｈｃ３ｓ）或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物，以及使用彼等之方法
Fawaz et al. Comparative in vitro–in vivo study of two quinine rectal gel formulations
KR20240041285A (ko) 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템
CN101951884A (zh) 用于治疗膀胱癌的含戊柔比星的膀胱内剂型组合物
De Caluwé et al. Pure alcohol injection of a congenital splenic cyst: a valid alternative?
WO2020210809A1 (en) Composition and methods for rectal delivery of 4-aapa and 5-asa compounds
BR112021001674A2 (pt) sistema de nanopartícula de dispersão mucoadesiva e método para a produção do mesmo
CN112469420A (zh) 减少关节内类固醇的并发症的方法
JP2025521859A (ja) 経口投与可能な医薬剤形および高シュウ酸尿症の治療方法におけるその使用
Jackson et al. LYTIC PHAGE ATTENUATES COLITIS SEVERITY IN GNOTOBIOTIC MICE COLONIZED WITH IBD-ASSOCIATED E. COLI NRG857C
CN118252797A (zh) 一种布地奈德黏性口服溶液、制备方法及其应用
CN104546949A (zh) 一种治疗溃疡性结肠炎改进型复合药物配方
TWI787189B (zh) 用於治療膀胱癌之配方
WO2023287309A1 (en) Pharmaceutical composition in the form of vegetable oil-based nanoemulsion, multiphase composition and method of preparation of these compositions
WO2024194781A1 (en) Improved compositions
JP2008501785A (ja) 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
Jøraholmen Development of chitosan-coated liposomes for improved therapy of vaginal infections: clotrimazole as model drug
HK40041258A (en) Methods to reduce complications of intra-articular steroid

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)